Do HMG-CoA reductase inhibitors affect fibrinogen?

scientific article

Do HMG-CoA reductase inhibitors affect fibrinogen? is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1345/APH.10211
P698PubMed publication ID11215845
P5875ResearchGate publication ID12115211

P2093author name stringC M White
J C Song
P2860cites workPrevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study GroupQ29619842
Simvastatin in severe hypercholesterolaemia: a placebo controlled trialQ34358043
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.Q34429041
Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemiaQ34439645
Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: cohort studyQ36246409
Method for the determination of functional (clottable) fibrinogen by the new family of ACL coagulometersQ36434446
Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study GroupQ39522420
Lovastatin Alters Blood Rheology in Primary Hyperlipoproteinemia: Dependence on Lipoprotein(a)?Q46602143
Blood viscosity and elevated carotid intima-media thickness in men and women: the Edinburgh Artery Study.Q50890944
Fibrinogen is an independent marker for thoracic aortic atherosclerosis.Q50907848
Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients.Q51552694
Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.Q51576971
Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.Q51581527
Fibrinogen and risk of cardiovascular disease. The Framingham Study.Q52588834
P433issue2
P407language of work or nameEnglishQ1860
P304page(s)236-241
P577publication date2001-02-01
P1433published inAnnals of PharmacotherapyQ4767858
P1476titleDo HMG-CoA reductase inhibitors affect fibrinogen?
P478volume35

Reverse relations

cites work (P2860)
Q36608415Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions.
Q37870867Chronic Chlamydia pneumoniae infection in patients with coronary disease. Relation with increased fibrinogen values
Q34979669Early statin therapy for acute coronary syndromes
Q44003335Effect of ciprofibrate on C-reactive protein and fibrinogen levels
Q35200997Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes
Q44378136Hemostatic effects of atorvastatin versus simvastatin
Q42754391Hemostatic effects of simvastatin in subjects with impaired fasting glucose.
Q44479268The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study
Q36059492The role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in modern rheumatology